MX393931B - Composiciones y usos de las mismas para inmunoterapia. - Google Patents

Composiciones y usos de las mismas para inmunoterapia.

Info

Publication number
MX393931B
MX393931B MX2019013500A MX2019013500A MX393931B MX 393931 B MX393931 B MX 393931B MX 2019013500 A MX2019013500 A MX 2019013500A MX 2019013500 A MX2019013500 A MX 2019013500A MX 393931 B MX393931 B MX 393931B
Authority
MX
Mexico
Prior art keywords
compositions
immunoresponsive cells
antigen receptors
immunotherapy
antigen
Prior art date
Application number
MX2019013500A
Other languages
English (en)
Spanish (es)
Other versions
MX2019013500A (es
Inventor
Hollie J Jackson
Renier J Brentjens
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2019013500A publication Critical patent/MX2019013500A/es
Publication of MX393931B publication Critical patent/MX393931B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
MX2019013500A 2013-02-26 2014-02-26 Composiciones y usos de las mismas para inmunoterapia. MX393931B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361769543P 2013-02-26 2013-02-26
PCT/US2014/018667 WO2014134165A1 (en) 2013-02-26 2014-02-26 Compositions and methods for immunotherapy

Publications (2)

Publication Number Publication Date
MX2019013500A MX2019013500A (es) 2020-01-20
MX393931B true MX393931B (es) 2025-03-24

Family

ID=51428766

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019013500A MX393931B (es) 2013-02-26 2014-02-26 Composiciones y usos de las mismas para inmunoterapia.
MX2015011095A MX378463B (es) 2013-02-26 2014-02-26 Composiciones y usos de las mismas para inmunoterapia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015011095A MX378463B (es) 2013-02-26 2014-02-26 Composiciones y usos de las mismas para inmunoterapia.

Country Status (28)

Country Link
US (3) US10124023B2 (enExample)
EP (2) EP2961831B1 (enExample)
JP (5) JP6535602B2 (enExample)
KR (5) KR20210108497A (enExample)
CN (3) CN113684185A (enExample)
AU (3) AU2014223601B9 (enExample)
BR (1) BR112015020516A2 (enExample)
CA (1) CA2902370C (enExample)
CY (1) CY1123326T1 (enExample)
DK (1) DK2961831T3 (enExample)
ES (1) ES2823586T3 (enExample)
HR (1) HRP20201419T1 (enExample)
HU (1) HUE050787T2 (enExample)
IL (4) IL298125A (enExample)
LT (1) LT2961831T (enExample)
MX (2) MX393931B (enExample)
MY (1) MY175869A (enExample)
PH (1) PH12015501880A1 (enExample)
PL (1) PL2961831T3 (enExample)
PT (1) PT2961831T (enExample)
RS (1) RS60759B1 (enExample)
RU (1) RU2680010C2 (enExample)
SA (2) SA517381708B1 (enExample)
SG (2) SG11201506964SA (enExample)
SI (1) SI2961831T1 (enExample)
SM (1) SMT202000536T1 (enExample)
WO (1) WO2014134165A1 (enExample)
ZA (2) ZA201506511B (enExample)

Families Citing this family (253)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
IL298125A (en) * 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
EP4098275A1 (en) * 2013-03-15 2022-12-07 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
DK2982681T3 (en) 2013-03-29 2018-12-10 Sumitomo Dainippon Pharma Co Ltd WT1 ANTIGENPEPTIDKONJUGATVACCINE
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
BR112016014410A2 (pt) 2013-12-20 2018-02-20 The Broad Institute Inc. terapia de combinação com vacina de neoantígeno
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
MX382541B (es) 2014-04-23 2025-03-13 Juno Therapeutics Inc Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva.
SG11201609118RA (en) 2014-05-15 2016-11-29 Univ Singapore Modified natural killer cells and uses thereof
MX390943B (es) 2014-07-21 2025-03-21 Novartis Ag Receptores de antígeno quimérico cd33 y usos de los mismos.
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
JP6945444B2 (ja) 2014-08-08 2021-10-06 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性ｐｄ−１薬剤とその使用方法
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
JP6839074B2 (ja) * 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
AU2015336029B2 (en) 2014-10-20 2021-07-22 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
BR112017008710A8 (pt) * 2014-10-27 2023-04-25 Hutchinson Fred Cancer Res Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
HK1243333A1 (zh) * 2014-10-31 2018-07-13 The Trustees Of The University Of Pennsylvania 用於修饰的t细胞的方法和组合物
SG11201704549UA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
CN113388036A (zh) 2014-12-05 2021-09-14 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的抗体及其用途
SG11201704550XA (en) * 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
IL302660B2 (en) 2014-12-19 2025-10-01 Dana Farber Cancer Inst Inc Chimeric antigen receptors and methods of using them
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
CN107249604A (zh) * 2014-12-31 2017-10-13 人类起源公司 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
WO2016123578A1 (en) 2015-01-30 2016-08-04 The Regents Of The University Of California Protein delivery in primary hematopoietic cells
EP4134430A1 (en) 2015-02-06 2023-02-15 National University of Singapore Methods for enhancing efficacy of therapeutic immune cells
US20170151281A1 (en) * 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
EP3089761B1 (en) 2015-03-02 2019-06-12 Innovative Cellular Therapeutics Co., Ltd. Reducing immune tolerance induced by pd l1
CA2981304C (en) * 2015-04-02 2024-01-02 Memorial Sloan Kettering Cancer Center Tnfrsf14/hvem proteins and methods of use thereof
TWI719019B (zh) 2015-04-15 2021-02-21 美商展望憑照看護公司亦以羅傑威廉斯醫療中心名稱營業 Car-t細胞之肝動脈灌注
JP2018518459A (ja) * 2015-04-30 2018-07-12 ユニバーシティ オブ サザン カリフォルニア 分泌性ｔｎｔ ｃａｒ細胞免疫療法
PT3298033T (pt) 2015-05-18 2020-09-22 Tcr2 Therapeutics Inc Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão
BR112017024797A2 (pt) 2015-05-20 2018-08-07 The Broad Institute Inc. neoantígenos partilhados
EP3299028B1 (en) * 2015-05-20 2024-10-30 Sumitomo Pharma Co., Ltd. Combination of wt1 antigen peptide, immunomodulator and wt1 helper peptide
EP3436575A1 (en) 2015-06-18 2019-02-06 The Broad Institute Inc. Novel crispr enzymes and systems
CA3006224A1 (en) * 2015-06-23 2016-12-29 Memorial Sloan-Kettering Cancer Center Novel pd-1 immune modulating agents
DK3313874T3 (da) * 2015-06-26 2021-05-03 Univ Southern California Maskering af kimære antigen-receptor t-celler til tumorspecifik aktivering
WO2017023801A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
CN105111314B (zh) * 2015-08-13 2019-01-08 成都百世博生物技术有限公司 一种新型融合蛋白、药物组合物及其制备方法和用途
US10428145B2 (en) 2015-09-29 2019-10-01 Celgene Corporation PD-1 binding proteins and methods of use thereof
SG10201913576RA (en) 2015-10-01 2020-02-27 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CN106350533B (zh) * 2015-10-09 2020-07-17 上海宇研生物技术有限公司 Anti-PD-L1-CAR-T及其制备方法和应用
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
US10533157B1 (en) 2015-12-03 2020-01-14 Nantbio, Inc. Recombinant NK cells expressing co-stimulatory molecules
NZ743124A (en) 2015-12-04 2022-11-25 Memorial Sloan Kettering Cancer Center Antibodies targeting fc receptor-like 5 and methods of use
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
CA3014001A1 (en) * 2016-02-25 2017-08-31 Cell Medica Switzerland Ag Binding members to pd-l1
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
WO2017192924A1 (en) 2016-05-04 2017-11-09 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
CN105950561A (zh) * 2016-05-26 2016-09-21 江苏杰晟生物科技有限公司 一种靶向乳腺癌干细胞的双特异性嵌合抗原受体基因修饰的t淋巴细胞的制备方法及其产品
JP2019517518A (ja) 2016-06-03 2019-06-24 メモリアル スローン ケタリング キャンサー センター 早期治療選択肢としての養子細胞療法
WO2017213979A1 (en) * 2016-06-06 2017-12-14 St. Jude Children's Research Hospital Anti-cd7 chimeric antigen receptor and method of use thereof
CN114891751A (zh) * 2016-06-20 2022-08-12 上海细胞治疗研究院 一种高效稳定表达激活型抗体的car-t细胞及其用途
CN107523545A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的杀伤性细胞及其用途
CN107523547A (zh) * 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抑制性抗体的car‑t细胞及其用途
CN110087672A (zh) 2016-07-29 2019-08-02 朱诺治疗学股份有限公司 免疫调节多肽及相关组合物和方法
MX2019001184A (es) * 2016-07-29 2019-09-26 Juno Therapeutics Inc Anticuerpos anti-idiotípicos y métodos relacionados.
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
MX2019002867A (es) 2016-09-19 2019-11-12 Celgene Corp Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
EP4353319A3 (en) * 2016-09-28 2024-06-05 Atossa Therapeutics, Inc. Methods of adoptive cell therapy
CA3037086A1 (en) 2016-10-03 2018-04-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
CN107964549B (zh) * 2016-10-20 2020-12-08 上海恒润达生生物科技有限公司 靶向cd22的嵌合抗原受体及其用途
WO2018081784A1 (en) * 2016-10-31 2018-05-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for expanding immune cells for immunotherapy
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
AU2017363278B2 (en) 2016-11-22 2022-10-27 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
KR20250072712A (ko) 2016-12-02 2025-05-26 앤젤레스 테라퓨틱스, 인코포레이티드 합성 면역 수용체 및 이의 사용 방법
US20190350978A1 (en) 2016-12-05 2019-11-21 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
MX2019007404A (es) 2016-12-23 2019-09-27 Macrogenics Inc Moleculas de union a adam9 y metodos de uso de las mismas.
EP3567049A4 (en) 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN108395478A (zh) * 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
EP4287191A3 (en) 2017-02-12 2024-03-06 BioNTech US Inc. Hla-based methods and compositions and uses thereof
CN110300603B (zh) * 2017-02-14 2023-04-14 亘喜生物科技（上海）有限公司 Cd47-car-t细胞
CN108424461B (zh) * 2017-02-14 2023-03-31 亘喜生物科技（上海）有限公司 Cd47-car-t细胞
CA3052779A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2018157164A1 (en) 2017-02-27 2018-08-30 Shattuck Labs, Inc. Csf1r-based chimeric proteins
CN110290798B (zh) 2017-02-27 2024-04-05 沙塔克实验室有限公司 基于vsig8的嵌合蛋白
CN118994414A (zh) 2017-02-27 2024-11-22 沙塔克实验室有限公司 基于tigit和light的嵌合蛋白
RU2019128544A (ru) 2017-03-27 2021-04-28 Нэшнл Юниверсити Оф Сингапур Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
CN110636851B (zh) 2017-03-27 2023-11-03 新加坡国立大学 截短的nkg2d嵌合受体及其在自然杀伤细胞免疫疗法中的用途
CN107082812B (zh) * 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
EP3606518A4 (en) 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
CN118370809A (zh) 2017-04-03 2024-07-23 百欧恩泰美国公司 蛋白质抗原及其用途
EP3610266A4 (en) 2017-04-12 2021-04-21 Massachusetts Eye and Ear Infirmary TUMOR SIGNATURE FOR METASTASIS, COMPOSITIONS OF MATERIAL AND THEIR METHODS OF USE
EP3612629A1 (en) 2017-04-18 2020-02-26 The Broad Institute, Inc. Compositions for detecting secretion and methods of use
WO2018195348A1 (en) * 2017-04-19 2018-10-25 University Of Southern California Compositions and methods for treating cancer
WO2018200583A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
EP3622092A4 (en) 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
WO2018213467A1 (en) 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
CN108864286B (zh) * 2017-05-16 2023-08-29 上海恒润达生生物科技股份有限公司 靶向cd19的嵌合抗原受体及联合表达抗pd1抗体可变区的方法和及其用途
US12297436B2 (en) 2017-05-18 2025-05-13 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US10780119B2 (en) 2017-05-24 2020-09-22 Effector Therapeutics Inc. Methods and compositions for cellular immunotherapy
CN107164410B (zh) * 2017-05-27 2019-09-03 上海优卡迪生物医药科技有限公司 一种基于octs技术的前列腺癌car-t治疗载体及其构建方法和应用
CN107245500B (zh) * 2017-05-27 2019-05-17 上海优卡迪生物医药科技有限公司 一种基于octs技术的淋系白血病car-t治疗载体及其构建方法和应用
CN107325185B (zh) * 2017-06-06 2019-09-20 上海优卡迪生物医药科技有限公司 基于octs-car的抗psca及pdl1双靶向嵌合抗原受体、编码基因及表达载体
CN107337736B (zh) * 2017-06-06 2019-07-26 上海优卡迪生物医药科技有限公司 Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用
EP3638218A4 (en) 2017-06-14 2021-06-09 The Broad Institute, Inc. COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
KR20240147708A (ko) 2017-07-11 2024-10-08 콤파스 테라퓨틱스 엘엘씨 인간 cd137에 결합하는 작동자 항체 및 이의 용도
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
CN107245107B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd20的嵌合抗原受体及其应用
CN107245106B (zh) * 2017-07-18 2020-06-12 深圳市免疫基因治疗研究院 一种基于cd10的嵌合抗原受体及其应用
CN107337737B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种嵌合抗原受体及其应用
CN107312098B (zh) * 2017-07-18 2020-06-12 深圳市免疫基因治疗研究院 一种基于cd22的嵌合抗原受体及其应用
CA3071282A1 (en) 2017-08-10 2019-02-14 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
MX2020002649A (es) 2017-09-11 2020-09-25 Atossa Therapeutics Inc Metodos para hacer y usar endoxifeno.
CN107557336B (zh) * 2017-09-15 2020-02-14 山东兴瑞生物科技有限公司 一种抗muc16安全型嵌合抗原受体修饰的免疫细胞及其应用
JP2020535802A (ja) 2017-09-21 2020-12-10 ザ・ブロード・インスティテュート・インコーポレイテッド 標的化核酸編集のための系、方法、及び組成物
CN109554349B (zh) * 2017-09-27 2022-06-24 亘喜生物科技（上海）有限公司 Pd-1基因表达沉默的工程化免疫细胞
CN109554348A (zh) * 2017-09-27 2019-04-02 亘喜生物科技（上海）有限公司 可诱导分泌抗cd47抗体的工程化免疫细胞
US12065498B2 (en) 2017-09-29 2024-08-20 Cell Design Labs, Inc. Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same
CN109593721B (zh) * 2017-09-30 2022-11-01 亘喜生物科技（上海）有限公司 具有自杀基因开关的靶向人间皮素的工程化免疫细胞
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
AU2018345539A1 (en) 2017-10-03 2020-04-16 Editas Medicine, Inc. HPV-specific binding molecules
US20210069241A1 (en) 2017-10-20 2021-03-11 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
DK3703750T3 (da) 2017-11-01 2025-02-10 Juno Therapeutics Inc Kimæriske antigenreceptorer, der er specifikke for b-cellemodningsantigen, og som koder for polynukleotider
KR20200099137A (ko) 2017-11-06 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법 및 감마 세크레타제 억제제의 조합
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
CN111655270A (zh) * 2017-11-14 2020-09-11 纪念斯隆-凯特琳癌症中心 分泌il-36的免疫应答细胞及其用途
US11649294B2 (en) * 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN109467603B (zh) * 2017-11-14 2020-02-21 拜西欧斯（北京）生物技术有限公司 抗pd-1抗体及其制备方法和应用
CN111655732B (zh) 2017-11-14 2023-09-12 Gc细胞治疗 抗her2抗体或其抗原结合片段及包含其的嵌合抗原受体
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
CN109971725B (zh) * 2017-12-28 2024-02-02 上海细胞治疗研究院 抗体修饰的嵌合抗原受体修饰t细胞及其用途
CN109971722B (zh) * 2017-12-28 2023-09-01 上海细胞治疗研究院 靶向cd19且高水平稳定表达cd40抗体的car-t细胞及其用途
CN109971716B (zh) * 2017-12-28 2023-08-01 上海细胞治疗研究院 自分泌cd47抗体的egfr特异性car-t细胞及其用途
CN109971721B (zh) * 2017-12-28 2023-10-31 上海细胞治疗研究院 自表达cd47抗体的间皮素特异性car-t细胞及其用途
MX2020006834A (es) * 2017-12-29 2020-09-03 Memorial Sloan Kettering Cancer Center Receptores mejorados de antigeno quimerico y usos de los mismos.
WO2019134036A1 (en) 2018-01-03 2019-07-11 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
WO2019136305A1 (en) * 2018-01-04 2019-07-11 Neumedicines Inc. Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
US20210023134A1 (en) * 2018-01-15 2021-01-28 Pfizer Inc. Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist
CA3089170A1 (en) 2018-02-09 2019-08-15 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3768700A1 (en) 2018-03-23 2021-01-27 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
CN112105731B (zh) 2018-03-30 2024-08-30 日内瓦大学 微小rna表达构建体及其用途
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
CN112585276A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
CA3095027A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
JP7584127B2 (ja) * 2018-04-26 2024-11-15 ベイラー カレッジ オブ メディスン 活性化された病原性ｔ細胞およびｎｋ細胞の選択的標的化のための自己／同種免疫防御受容体
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
MY208825A (en) 2018-06-13 2025-05-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
WO2019246563A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
CA3109630A1 (en) * 2018-08-16 2020-02-20 Memorial Sloan-Kettering Cancer Center Leucine zipper-based compositions and methods of use
WO2020041384A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
EP3856769A4 (en) * 2018-09-28 2022-08-17 Memorial Sloan Kettering Cancer Center IMMUNOREACTIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
US20210388389A1 (en) 2018-10-30 2021-12-16 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
JP2022513412A (ja) * 2018-10-31 2022-02-07 ヒューマニゲン インコーポレイティッド 癌を治療するための物質及び方法
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
WO2020095113A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
CA3118027A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd. Humanized and variant tgf-.beta.3 specific antibodies and methods and uses thereof
SG11202104864QA (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
US20210393692A1 (en) * 2018-11-13 2021-12-23 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer
CN120519520A (zh) * 2018-11-14 2025-08-22 麦迪赛克斯医疗私人有限公司 用于生成car-t细胞的两类基因载体及其用途
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
AU2019404547B2 (en) 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US20220128541A1 (en) * 2019-02-14 2022-04-28 Research Institute At Nationwide Children's Hospital Use of plasma membrane particles, liposomes, and exosomes to assay immune cell potency
SG11202109057XA (en) 2019-03-05 2021-09-29 Nkarta Inc Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2020188348A2 (en) 2019-03-18 2020-09-24 Ludwig Institute For Cancer Research Ltd A2/ny-eso-1 specific t cell receptors and uses thereof
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
WO2020226854A2 (en) * 2019-04-12 2020-11-12 The Johns Hopkins University Tolerogenic artificial antigen-presenting cells
WO2020214957A1 (en) 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anti-pd-1 antibodies and uses thereof
WO2020227538A1 (en) * 2019-05-08 2020-11-12 Memorial Sloan Kettering Cancer Center Humanized antibodies to mucin-16 and methods of use thereof
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
US12448462B2 (en) 2019-06-14 2025-10-21 Dana-Farber Cancer Institute, Inc. Antibodies against MUC1
CA3143599A1 (en) * 2019-06-17 2020-12-24 Enochian BioPharma, Inc. Allogeneic t-cell-based hiv vaccine to induce cellular and humoral immunity
WO2020257823A2 (en) 2019-06-21 2020-12-24 Kite Pharma, Inc. TGF-β RECEPTORS AND METHODS OF USE
EP3993782A4 (en) 2019-07-03 2023-08-02 Atossa Therapeutics, Inc. EXTENDED RELEASE ENDOXIFEN COMPOSITIONS
CN110343667A (zh) * 2019-07-17 2019-10-18 贝赛尔特(北京)生物技术有限公司 工程化的免疫细胞及其制备方法和应用
US20210040175A1 (en) * 2019-08-05 2021-02-11 Nantkwest, Inc. Artificial Target Cells for in-vitro CAR Cytotoxicity and ADCC validation
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
AU2020345943A1 (en) 2019-09-10 2022-03-31 Obsidian Therapeutics, Inc. CA2-IL15 fusion proteins for tunable regulation
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
CN114901677A (zh) * 2019-11-04 2022-08-12 艾诺奥医药品有限公司 治疗脑癌的联合疗法
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CN112079934B (zh) * 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
US20230058519A1 (en) * 2019-12-28 2023-02-23 Shanghai Cell Therapy Group Company Co., Ltd. Cell Expressing Immune Modulatory Molecules and System for Expressing Immune Modulatory Molecules
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
TW202216193A (zh) * 2020-06-22 2022-05-01 德商莫菲西斯公司 包含抗CD19抗體及阻斷SIRPα-CD47先天免疫檢查點之多肽之抗腫瘤組合療法
CN116583607A (zh) 2020-08-13 2023-08-11 耶鲁大学 用于工程改造和选择具有期望表型的car t细胞的组合物和方法
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
EP4203980A1 (en) * 2020-08-28 2023-07-05 Innovative Cellular Therapeutics Holdings, Ltd. Fusion protein enhancing cell therapy
CN111925990B (zh) * 2020-09-02 2022-08-26 北京立康生命科技有限公司 一种针对卵巢癌的Anti-MUC16 CAR-T细胞及其制备方法
EP4222175A4 (en) * 2020-09-29 2024-12-11 Nanjing Legend Biotech Co., Ltd. T-CELL AND ANTIGEN-PRESENTING CELL ENGAGERS AND USES THEREOF
KR20230104222A (ko) 2020-11-06 2023-07-07 노파르티스 아게 B 세포 악성종양 치료를 위한 항-cd19 작용제 및 b 세포 표적화제 병용 요법
US11617767B2 (en) 2020-11-20 2023-04-04 Simcere Innovation, Inc. Armed dual CAR-T compositions and methods for cancer immunotherapy
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
AU2022237618A1 (en) 2021-03-17 2023-10-12 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
CA3216524A1 (en) * 2021-04-12 2022-10-20 Medgene Therapeutics, Inc. A method of activating and proliferating exhausted cd8 t cells, cd8 t cells with enhanced activity prepared by the same, and use thereof
WO2022235832A1 (en) 2021-05-06 2022-11-10 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
CA3218780A1 (en) 2021-05-11 2022-11-17 Daniel Getts Methods and compositions for genomic integration
AU2022271801A1 (en) * 2021-05-13 2023-11-09 Memorial Sloan Kettering Cancer Center Nkg2c+ t cells and methods of use thereof
MX2024001948A (es) 2021-08-13 2024-05-17 Inovio Pharmaceuticals Inc Terapia combinada para tratar el cáncer cerebral.
US20250228940A1 (en) 2022-03-11 2025-07-17 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
US20250161360A1 (en) 2022-05-10 2025-05-22 Yale University Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
EP4541369A4 (en) * 2022-06-15 2025-08-20 Cellid Co Ltd Vaccine comprising natural killer cells loaded with ligands of natural killer t cells and cancer antigens
US20250375502A1 (en) * 2022-06-22 2025-12-11 Wuhan Houxian Biopharmaceutical Co. Ltd. Combination of il-12 and ox40l for cancer immunotherapy
WO2024064824A2 (en) 2022-09-21 2024-03-28 Yale University Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
CN115850519B (zh) * 2022-12-12 2023-06-23 南京市浦口医院 一种靶向MAGE-A1且自分泌CD47 scFv的嵌合抗原受体及其应用
WO2024155821A1 (en) 2023-01-18 2024-07-25 Yale University Chimeric antigen receptors (car) with intrinsically disordered regions and methods of use thereof
KR20250131823A (ko) 2023-03-31 2025-09-03 아벨제타 인크. Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체
WO2024226829A2 (en) 2023-04-26 2024-10-31 Yale University Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
WO2024238656A1 (en) 2023-05-15 2024-11-21 Yale Univeristy Chimeric antigen receptor compositions, car-mast cells formed therefrom, and methods of use thereof
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025158400A1 (en) 2024-01-24 2025-07-31 Yale University Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA8748A (en) 1878-05-04 George W. Ainsworth Improvements on clothes dryers
CA59350A (en) 1898-02-26 1898-03-19 Thomas Henry Simmonds Brake for velocipede, tricycle, etc.
CA95152A (en) 1905-02-28 1905-09-19 Carl Weilbier Insulated glove
CA138738A (en) 1910-12-30 1912-02-27 The United Shoe Machinery Company Of Canada Metal fastening machine
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
CN1155843A (zh) * 1995-04-07 1997-07-30 巴斯德梅里厄血清及疫苗公司 诱导粘膜免疫应答的组合物
JP2001516766A (ja) * 1997-09-19 2001-10-02 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 免疫反応の細胞内発現抗体仲介制御
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
ATE524495T1 (de) 2001-07-31 2011-09-15 Ono Pharmaceutical Co Pd-1-spezifische substanz
AU2003257419B2 (en) * 2002-06-13 2010-02-25 Crucell Holland, B.V. OX40 (CD134) receptor agonistic and therapeutic use
ES2345200T3 (es) * 2003-03-24 2010-09-17 The Scripps Research Institute Vacunas de adn contra el crecimiento tumoral y procedimientos de utilizacion de las mismas.
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
JP6092497B2 (ja) * 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
SI2856876T1 (en) * 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
CA3002192C (en) 2010-03-26 2023-03-07 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA3102782A1 (en) * 2010-12-14 2012-06-21 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
JP6130307B2 (ja) * 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
MX359513B (es) * 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
EP3915588A1 (en) 2011-07-29 2021-12-01 The Trustees of the University of Pennsylvania Switch costimulatory receptors
MX370148B (es) * 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
IL298125A (en) 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy

Also Published As

Publication number Publication date
RS60759B1 (sr) 2020-10-30
NZ711766A (en) 2021-06-25
ES2823586T3 (es) 2021-05-07
CA2902370C (en) 2023-03-14
MX378463B (es) 2025-03-10
CN105874061B (zh) 2021-08-10
ZA201808085B (en) 2021-01-27
JP6535602B2 (ja) 2019-06-26
SA517381708B1 (ar) 2021-07-17
SA515360944B1 (ar) 2019-04-07
IL281817A (en) 2021-05-31
JP2023107931A (ja) 2023-08-03
IL240799A0 (en) 2015-10-29
JP2016508728A (ja) 2016-03-24
AU2014223601B9 (en) 2020-04-23
IL289821B2 (en) 2023-04-01
EP2961831A1 (en) 2016-01-06
US20160045551A1 (en) 2016-02-18
MX2019013500A (es) 2020-01-20
US20190083534A1 (en) 2019-03-21
CN113699114A (zh) 2021-11-26
KR102363191B1 (ko) 2022-02-17
HUE050787T2 (hu) 2021-01-28
SI2961831T1 (sl) 2020-10-30
IL289821B (en) 2022-12-01
JP2018157836A (ja) 2018-10-11
KR20150121714A (ko) 2015-10-29
PT2961831T (pt) 2020-10-12
NZ751082A (en) 2021-06-25
EP2961831A4 (en) 2016-10-05
BR112015020516A2 (pt) 2017-10-10
KR20230152160A (ko) 2023-11-02
HRP20201419T1 (hr) 2020-12-11
ZA201506511B (en) 2022-08-31
SG10202001030VA (en) 2020-04-29
HK1219976A1 (en) 2017-04-21
IL298125A (en) 2023-01-01
DK2961831T3 (da) 2020-09-07
JP7367104B2 (ja) 2023-10-23
KR20210108497A (ko) 2021-09-02
CN105874061A (zh) 2016-08-17
RU2680010C2 (ru) 2019-02-14
IL281817B (en) 2022-02-01
MX2015011095A (es) 2016-03-11
AU2014223601A1 (en) 2015-09-24
SMT202000536T1 (it) 2020-11-10
US10124023B2 (en) 2018-11-13
LT2961831T (lt) 2020-11-10
RU2019103572A (ru) 2019-06-24
EP2961831B1 (en) 2020-06-10
AU2014223601B2 (en) 2020-04-02
CA2902370A1 (en) 2014-09-04
MY175869A (en) 2020-07-14
RU2015140811A (ru) 2017-04-03
KR20220134786A (ko) 2022-10-05
CY1123326T1 (el) 2021-12-31
AU2022275398A1 (en) 2023-01-05
US11103531B2 (en) 2021-08-31
EP3811954A1 (en) 2021-04-28
JP2022069603A (ja) 2022-05-11
IL289821A (en) 2022-03-01
JP2020054387A (ja) 2020-04-09
CN113684185A (zh) 2021-11-23
PL2961831T3 (pl) 2020-12-14
WO2014134165A1 (en) 2014-09-04
PH12015501880A1 (en) 2016-01-11
KR20200113284A (ko) 2020-10-06
SG11201506964SA (en) 2015-10-29
US20210369781A1 (en) 2021-12-02
AU2020204448A1 (en) 2020-07-23
KR102593475B1 (ko) 2023-10-26
IL240799B (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MX378463B (es) Composiciones y usos de las mismas para inmunoterapia.
PH12018502113A1 (en) Chimeric receptors and methods of use thereof
MX2023013729A (es) Receptores quimericos de flt3 y metodos de uso de los mismos.
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
MX2020002694A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
EA201690443A1 (ru) Биспецифические моновалентные диатела, которые способны связываться с cd123 и cd3, и их применения
MX391989B (es) Conjugados de amatoxina y anticuerpos.
EA201791485A1 (ru) Анти-cd47-антитела и их применения
TR201905458T4 (tr) Fap ve dr5 için spesifik bispesifik antikorlar, dr5 için spesifik antikorlar ve bunların kullanım yöntemleri.
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
EA201591740A1 (ru) Вирусы болезни ньюкасла и их применение
MX2016001093A (es) Nanoemulsion de aminosilicona.
EA202193044A2 (ru) Способы лечения таупатии
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
MX2016001094A (es) Nanoemulsion de aminosilicona.
TN2012000366A1 (en) Anticoagulant antidotes
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
WO2015009715A3 (en) Molecular and cellular imaging using engineered hemodynamic responses
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
TN2013000388A1 (en) Anticoagulant antidotes
MX2016004420A (es) Proteinas de union especificas duales dirigidas contra los receptores de células inmunes y autoantígenos de señalización de tlr.